Vulvar melanoma

Summary

Vulvar melanoma (MONDO:0002205) is a cancer and 1 clinical trial. Top therapeutic interventions include cabozantinib. A subtype of vulva cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vulvar melanoma
Mondo ID	MONDO:0002205
DOID	DOID:2093
NCIT	C40329
SNOMED CT	254896002
UMLS	C0241989
MedGen	66040
GARD	0027599
Anatomy (UBERON)	UBERON:0000997
Is cancer (heuristic)	yes

Also known as: mammalian vulva melanoma · mammalian vulva melanoma (disease) · melanoma (disease) of mammalian vulva · vulvar melanoma · vulvar melanoma (disease)

Data availability: 1 HPO phenotype · 1 cell line.

Disease family

This is a subtype of vulva cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › vulva cancer › vulvar melanoma

Related subtypes (7): labium majus cancer, labia minora cancer, paraurethral gland cancer, clitoris cancer, vulva sarcoma, vulvar carcinoma, mixed germ cell tumor of vulva

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05111574	PHASE2	RECRUITING	Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABOZANTINIB	4	3